Single test isolated lupus anticoagulant positivity is associated with increased plasma levels of inflammatory markers and dyslipidemia

Abstract

Objective

To investigate whether a single positive test for lupus anticoagulant (LA) is associated with levels of inflammatory markers and traditional cardiovascular risk factors, independent of autoimmune disease, thrombophilia and occurrence of other antiphospholipid antibodies.

Methods

In a retrospective observational study we included persons referred for thrombophilia testing during 2011−2014. Persons with autoimmune disease, thrombophilia or presence of specific anti-phospholipid antibodies were excluded. Multivariate logistic regression analyses adjusted for age and sex was performed and odds ratios (ORs) with 95% confidence intervals (95% CI) calculated.

Results

Of 381 individuals tested, 271 fulfilled the criteria, of whom 22 (8%) were LA positive and 249 (92%) LA negative. LA positivity was associated with higher body mass index (BMI) (OR 1.12, 95% CI: 1.03–1.23, p = 0.01); C-reactive protein (OR 1.08 95% CI:1.04–1.11, p < 0.001); fibrinogen (OR 1.51 95% CI: 1.27–1.78, p < 0.001); coagulation factor VIII (FVIII) (OR 1.73 95% CI: 1.01–2.96, p = 0.046), low high density lipoprotein (HDL) (OR 0.03 95% CI: 0.00–0.19, p < 0.001) and high triglyceride (OR 1.81 95% CI: 1.12–2.92, p = 0.02) compared with LA negative individuals.

Conclusion

This study shows that single test isolated LA positivity is associated with increased levels of inflammatory markers, low HDL cholesterol, elevated triglyceride and high BMI.

Keywords

Antiphospholipid antibodies lupus anticoagulant inflammation dyslipidemia

Get full access to this article

View all access options for this article.

References

Galli

Luciani

Bertolini

Barbui

. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827–1832.

Pengo

Testa

Martinelli

. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thrombosis Res 2015; 135: 46–49.

Levine

Branch

Rauch

. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752–763.

Giannakopoulos

Krilis

. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033–1044.

Aksu

Donmez

Keser

. Inflammation-induced thrombosis: mechanisms, disease associations and management. Current Pharmaceut Des 2012; 18: 1478–1493.

Pengo

Tripodi

Reber

. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–1740.

Pengo

Ruffatti

Del Ross

. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 2013; 11: 1527–1531.

Urbanus

Siegerink

Roest

Rosendaal

de Groot

Algra

. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8: 998–1005.

da Silva

Levy

de Carvalho

. Cardiovascular risk factors in the antiphospholipid syndrome. J Immunol Res 2014; 2014: 1–6.

10.

Samad

Ruf

. Inflammation, obesity, and thrombosis. Blood 2013; 122: 3415–3422.

11.

Liao

Playford

Frits

. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 2015; 4.

12.

Park

Cho

Emery

Kim

. LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis: a single-center prospective study. PloS one 2013; 8: e68975–e68975.

13.

de Carvalho

Bonfa

Borba

. Systemic lupus erythematosus and ‘lupus dyslipoproteinemia’. Autoimmun Rev 2008; 7: 246–250.

14.

Lynge

Sandegaard

Rebolj

. The Danish National Patient Register. Scand J Public Hlth 2011; 39: 30–3.

15.

Keeling

Mackie

Moore

Greer

Greaves

. British Committee for Standards in Health. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47–58.

16.

Sailer

Vormittag

Pabinger

. Inflammation in patients with lupus anticoagulant and implications for thrombosis. J Rheumatol 2005; 32: 462–468.

17.

Erkan

Willis

Murthy

. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2014; 73: 1176–1180.

18.

Simantov

LaSala

. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211–2219.

19.

Kaplanski

Cacoub

Farnarier

. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000; 43: 55–64.

20.

Pierangeli

Harris

. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 2003; 12: 539–545.

21.

Vega-Ostertag

Casper

Swerlick

Ferrara

Harris

Pierangeli

. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52: 1545–1554.

22.

Samarkos

Mylona

Kapsimali

. The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity. Semin Arthritis Rheum 2012; 42: 66–69.

23.

Pericleous

Ruiz-Limon

Romay-Penabad

. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology (Oxford) 2015; 54: 722–727.

24.

Darvall

Sam

Silverman

Bradbury

Adam

. Obesity and thrombosis. Euro J Vasc Endovasc Surg 2007; 33: 223–233.

25.

Rye

Barter

. Cardioprotective functions of HDLs. J Lipid Res 2014; 55: 168–179.

26.

Arnaud

Mathian

Devilliers

. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 2015; 14: 192–200.

27.

Vinholt

Nybo

. Interference from lupus anticoagulant on von Willebrand factor measurement in splenic marginal zone lymphoma: a case report. Blood Coag Fibrinolysis 2015; 26: 454–457.

28.

Jenkins

Rawley

Smith

O'Donnell

. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012; 157: 653–663.

29.

Schouwers

Delanghe

Devreese

. Lupus anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res 2010; 125: 102–104.